Aruma Labs teams up with Applied Cannabis Research for endometriosis observational study

Applied Cannabis Research, providing research expertise and services to medicinal cannabis companies

Australia’s leading contract research organization focused on medicinal cannabis treatments

200 women to take part to monitor the safety & efficacy of medical cannabis as a management option for refractory chronic pain, a common endometriosis symptom.

SYDNEY, NSW, AUSTRALIA, January 31, 2021 /EINPresswire.com/ — Applied Cannabis Research is pleased to announce Aruma Labs (Aruma) has joined Australia’s longest running observational study of medicinal cannabis products, the CA Clinics Observational Study (CACOS*), with a focus on collecting data from patients with endometriosis.

Endometriosis is a notoriously painful condition affecting more than 11% of Australian women, according to Endometriosis Australia. It is characterised by the presence of endometrial tissue, normally found inside the uterus, in other areas of the abdomen. The reduction in quality of life for women with endometriosis has been estimated at A$4 billion per annum (Ernst & Young (2019): The Cost of Endometriosis in Australia Report).

200 women will participate in the study to monitor the safety and efficacy of medicinal cannabis as an adjunct treatment and management option for refractory chronic pain, a common symptom of endometriosis.

KEY HIGHLIGHTS:
-200 Australian women will be recruited to participate in Applied Cannabis Research’s endometriosis observational study through CA Clinics
-Endometriosis is estimated to affect more than 11% of Australian women and the reduced quality of life is estimated to result in a societal cost of $4 billion a year
-Aruma will include their medicinal cannabis products in the study, and Applied Cannabis Research will collect data about its safety and efficacy, as well as tracking pain and quality of life (QOL) outcomes in patients prescribed an Aruma product
-The Endometriosis Study is a sub-study of CACOS, an observational study on the health outcomes of 3,000 patients nationwide at CA Clinics that are prescribed medicinal cannabis products for treatment of refractory conditions

Louis Williams, CEO of Aruma commented:
“Research shows that women with endometriosis often may wait up to eight years before they receive a diagnosis. During that time, they can suffer debilitating pain, depression, and a diminished quality of life. Our aim, through this partnership with Applied Cannabis Research, is to collect patient-reported data to understand whether our unique formulations have potential as a safe and effective treatment option in the ongoing management of the pain that often accompanies endometriosis. Aruma is committed to helping find solutions for patients that make a real and tangible difference to their lives.”

Dr John Barlow, Principal Investigator at Applied Cannabis Research commented: “Endometriosis is a chronic and debilitating condition affecting approximately 11% of women. It is characterized by infertility and chronic pelvic pain, yet treatment options remain limited. Medicinal cannabis is increasingly being used for the treatment of refractory pain but its efficacy as a therapeutic for endometrial pain is unknown. This observational study will first demonstrate the efficacy of cannabis to treat endometrial pain as well as indicating which cannabinoid formulations are the most potent.”

Dr Mark Hardy, Addiction Specialist and Medical Director at CA Clinics said:
“Chronic pain associated with endometriosis is a complex and debilitating problem for millions of women worldwide. The positive impacts of medical cannabis on pain are potent enough to consider medical cannabis as a pain management option, adjunct to current treatments. Cannabinoids are being researched for their impact on the processes of angiogenesis, a key aspect of the pathology of endometriosis, as well as their anti-inflammatory properties. The evidence-based research of CACOS is essential for better treatment and health outcomes.”

Dr Davina Hiley, CA Clinics, added:
"Many women suffer from distressing endometriosis symptoms. Common treatments such as hormonal therapy, analgesia, anti-inflammatories or even surgical intervention are often ongoing, and have their own set of risks and side effects. There's therefore a need to consider other therapeutic management options such as medicinal cannabis.”

Healthcare professionals and eligible patients over the age of 18 seeking more details regarding the Endometriosis Study or medicinal cannabis treatment pathways can contact CA Clinics at 1300 991 477 info@caclinics.com.au

FOR MEDIA ENQUIRIES: lisa.mclean@ajdmedia.com.au or call 0412 372 158

AVAILABLE FOR INTERVIEW:

-Louis Williams, Aruma CEO
-Dr Mark Hardy, Medical Director CA Clinics
-Dr John Barlow, Applied Cannabis Research
-Patient who has been prescribed medicinal cannabis for endometriosis

ABOUT ARUMA
Aruma is an Australian Life Sciences company that specialises in the research, development and production of high quality, cannabinoid-based therapeutics to treat unmet medical needs. Aruma aims to inspire hope and deliver therapeutic benefits for patient’s seeking safe, reliable alternative treatment options to traditional therapies.

*ABOUT CACOS (CA Clinics Observational Study)
CACOS aims to collect observational data on safety and health-related outcomes in patients being prescribed medicinal cannabis products through CA Clinics. It is an observational study that collects information from patients and their treating doctors about their health-related quality of life and any adverse events experienced with medicinal cannabis treatment. CACOS includes different products, from which data is being collected to describe and evaluate medicinal cannabis for a wide range of refractory conditions.

ABOUT APPLIED CANNABIS RESEARCH
Applied Cannabis Research, a division of Southern Cannabis Holdings, is a specialist contract research organisation providing research expertise and services to medicinal cannabis companies and others interested in the medicinal cannabis field. info@appliedcannabisresearch.com.au, (+61) 2 8294 6406 @CannabisApplied

Lisa McLean
AJD Media
+61 412 372 158
lisa.mclean@ajdmedia.com.au
Visit us on social media:
Twitter
LinkedIn


Source: EIN Presswire

Combination Kit includes SWS Socket Wrench Torque Sensor and PHM-100 Portable Handheld

CAL-TEDS Plug & Play Smart Sensors Icon

Our popular SWS (Socket Wrench Torque Sensor) and our PHM-100 Portable Hand-Held Transducer Indicator.

SWS / PHM-100 System

SOCKET WRENCH TORQUE SENSOR REACTION TYPE

SWS Series

Plug & Play Smart PORTABLE HAND HELD LOAD CELL INDICATOR

SSI Portable Handheld Load Cell Indicator

Fully Portable Hand-Held Transducer Indicator

TEMECULA, CALIFORNIA, UNITED STATES, January 30, 2021 /EINPresswire.com/ — New from Transducer Techniques an economically priced System combination comprising of our popular SWS (Socket Wrench Torque Sensor) and our PHM-100 Portable Hand Held Load Cell Indicator. This system provides accurate measurements of bolt or nut wrenching torques in either direction, so break-away torques can be measured.

The PHM-100 has a Peak Hold feature that captures at less than one millisecond and operates on a 9-volt battery for 60 hours. The SWS is a reaction type torque sensor offered in 6 ranges from 10 FT. LBS. to 1000 FT. LBS. full scale.

Accuracies are consistent with highly accurate strain gauge load cells.

https://www.transducertechniques.com

Customer Support
Transducer Techniques, LLC
+1 800-344-3965
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

Pradeep Balasubramanian on the Intricacies of Shoulder Surgery

Pradeep Balasubramanian of Dubai

Pradeep Balasubramanian of Dubai

Pradeep Balasubramanian is a Dubai based surgeon who specializes in Shoulder, Elbow, and Hand surgery

DUBAI, EMIRATE OF DUBAI, UAE, January 29, 2021 /EINPresswire.com/ — He was an AOA Fellow Shoulder Elbow and Hand Surgery at Lyell McEwin Health Services Foundation Inc. With a cumulative 15 years of orthopedic experience, he has developed a wealth of knowledge about musculoskeletal health, particularly in the complex structures of the shoulder, elbow, wrist, and hand. 

The shoulder is an area where practically many people can expect to have some kind of problem at some point in their life. With proper nutrition and exercise, most people can prevent these problems effectively. But of course, when injury or illness enters into the equation, surgeons like Pradeep Balasubramanian are here to help. We asked Pradeep Balasubramanian to discuss his thoughts on shoulder health and the intricacies of shoulder surgery.

Pradeep Balasubramanian of Dubai on Shoulder Surgery
Pradeep Balasubramanian explains that the structures of the shoulder, elbow, wrist, and hand are extremely complex with hundreds of tightly strung muscles, ligaments, tendons, nerves, arteries, and veins. With such complexity comes a strong likelihood of mechanical issues, which can predispose to injury. When an injury occurs, surgery may be needed if conservative treatment fails. Pradeep Balasubramanian discussed five different signs that may indicate a need for shoulder surgery.

Radiating Pain from the Shoulder Down the Arm to the Elbow
Mild pain in the shoulder is common and usually passing. If, however, that pain radiates down the arm to the elbow, other more structural problems are likely causal factors. 

Night Pain
If sleep is being lost due to a shoulder injury, this is a red flag that something more sinister exists inside. Persons who have night pain and whose sleep is disturbed due to the night pain should seek medical intervention as a general rule.

Weakness in the Shoulder or Arm
If a nerve is being impinged upon, or if muscles, ligaments, or cartilage have been damaged, weakness in the arm may result. Structural damage like this may need to be repaired through surgery. 

Pain Without Activity
Pain in the absence of significant work or activity indicates a longstanding problem. This may indicate issues that may need to be addressed through surgical intervention in many cases.

Impaired Function
Any loss of range of motion or other functionality of the shoulder and arm should be examined by a shoulder specialist as early as possible. If necessary, your general practitioner may recommend an examination by a shoulder specialist like Pradeep Balasubramanian.

Pradeep Balasubramanian of Dubai Shoulder Health Tips
Pradeep Balasubramanian explains that there is much that a person can do to prevent pain, stiffness, and damage to the shoulder and surrounding structures. First and foremost, he recommends proper nutrition and mild to moderate exercise. Supplementary to these is a regular, daily stretching routine. Pradeep Balasubramanian says, everyone should perform mild stretches on waking and before and after exercise. 

Finally, Pradeep Balasubramanian of Dubai recommends loading the shoulders with exercises such as pull ups or push ups. These vectors of exertion, he explains, are commonly missing from most people’s lives, but that it is an important way to maintain the strength and flexibility the shoulders needed to be healthy.

Caroline Hunter
Web Presence, LLC
+1 786-551-9491
email us here


Source: EIN Presswire

2021 ICare4Autism International Conference – ASD and Anxiety in Extraordinary Times

ICare4Autism International Online Conference 2021

Featured speakers at Icare4Autism’s national web-conference

The International Center for Autism Research and Education will host its annual autism conference online on March 10th, 2021

We are happy to be able to offer our top-notch content to anyone who was previously prevented from attending our events…I am certain our online format will be a great success.”

— Dr. Joshua Weinstein, Founder and CEO of ICare4Autism

NEW YORK, NY, USA, January 29, 2021 /EINPresswire.com/ — ICare4Autism has announced its 2021 Annual International Autism Conference, ASD and Anxiety in Extraordinary Times, to be held on March 10th, 2021, 8:30 AM – 4:30 PM EST. Hosted on Whova, an all-in-one event management app, the conference will take place virtually and feature speakers from around the world, who are top researchers and activists in the autism world. They will be discussing the rigors of anxiety on people who are on the autism spectrum, and the latest research about CBD and autism.

Conference speakers include the world-renowned Eric Hollander, M.D., Director – Autism and Obsessive-Compulsive Spectrum Program and Professor of Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine and Psychiatric Research Institute at Montefiore-Einstein; Hakon Hakonarson, M.D., Ph.D., Director of the Center for Applied Genomics, Endowed Chair in Genomics Research and Professor of Pediatrics at The University of Pennsylvania, Perelman School of Medicine; Stephen Shore, Ed.D., a full-time professor at Adelphi University and adjunct at NYU Steinhardt School of Culture, Education, and Human Development. Autism activists such as Merry Barua, Director, Action for Autism, National Centre for Autism, India, will also be speaking at the event.

Held annually for over fifteen years, ICare4Autism’s conferences are a teeming hub for scientists, activists, and educators in the autism world from around the globe to share their ideas and learn about the latest developments in the field of Autism Spectrum Disorder.

ICare4Autism hopes to reach its widest audience yet by hosting the conference online for the first time and allowing access to ticket-buyers worldwide. “We are happy to be able to offer our top-notch content to anyone who was previously prevented from attending our events due to geographic limitations,” said Dr. Joshua Weinstein, founder and CEO of the International Center for Autism Research and Education. “Even with the recent challenges of hosting such an event, we were able to secure the leading experts in the field of autism research and advocacy, and I am certain our online format will be a great success.”

ICare4Autism is offering Early Bird tickets until February 15th at $39/ticket and special discounts for parents, students, teachers, and groups. General Admission tickets are $69, and all conference content will be available to attendees for six months on the Whova app.

The conference is sponsored by Your CBD Store, Mitzva Wellness, Bioforum, and Primal Logic & Data Corp.

To learn more and purchase tickets visit: https://whova.com/web/icare_202102/

————————–

ICare4Autism serves as the lead global non-profit organization dedicated to improving the lives of children and adults who live with autism. Founded in 2004 by Dr. Joshua Weinstein, ICare4Autism has established itself as the catalyst that drives collaborations among similar international institutions to discover the etiology of autism, search for biologic and environmental causes, and ultimately work toward better methods of detection and treatment.

To learn more, visit ICare4Autism’s website: https://icare4autism.org

Yarden Shoval
The International Center for Autism Research and Education
+1 718-686-9600
email us here


Source: EIN Presswire

Applied Biology Receives IRB Approval to Study a Potential Breakthrough Therapy for Hospitalized COVID-19 Patients

Applied Biology

PROXALUTAMIDE AS A POTENITAL TREATMENT FOR HOSPITALIZED COVID-19 PATIENTS

IRVINE, CA, USA, January 28, 2021 /EINPresswire.com/ — Irvine, CA, January 28, 2021 — The Applied Biology team led by Flavio A. Cadegiani, MD, MSc, PhD, Andy Goren, MD, Carlos Wambier, MD, PhD along with other collaborators have recently concluded a randomized controlled study of Proxalutamide in the treatment of COVID-19 male outpatients. Two hundred and sixty two subjects were enrolled in the study. No subjects treated with Proxalutamide were hospitalized compared to 27% of the subjects treated with the standard of care alone. The results of the study have been submitted to a peer-reviewed medical journal for publication.

According to Dr. Goren “following on the promising results of Proxalutamide in the treatment of COVID-19 male outpatients, we decided to study Proxalutamide as a treatment for hospitalized COVID-19 patients not requiring mechanical ventilation.”

The study on the use of Proxalutamide for hospitalized COVID-19 male and female patients has received national IRB approval and will be conducted in several sites in Brazil.

According to Dr. Cadegiani “we are excited to commence this study that could potentially benefit millions of patients and change the course of COVID-19.”

More information about the study (ClinicalTrials.gov Identifier: NCT04728802) will be made available at clinicaltrials.gov.

The approval was received on January 27, 2021 from the IRB of the National Board of Ethics Committee (CONEP), from the Brazilian Ministry of Health, under the name “The Proxa-Rescue AndroCoV Trial”, number (CAAE) 41909121.0.0000.5553.

ABOUT APPLIED BIOLOGY
Founded in 2002, Applied Biology, Inc. (www.appliedbiology.com), headquartered in Irvine, California, is a biotechnology company specializing in hair and skin science. Applied Biology develops breakthrough drugs and medical devices for the treatment of androgen mediated dermatological conditions. Applied Biology's R&D pipeline includes a topically applied prophylactic treatment for chemotherapy induced alopecia; a novel diagnostic device that can aid dermatologists in identifying non-responders to topical minoxidil; an adjuvant therapy for non-responders to topical minoxidil; and a novel therapy for female pattern hair loss.

Monica Naegle
Applied Biology, Inc.
+1 949-387-4526
email us here
Visit us on social media:
Twitter
LinkedIn
Facebook


Source: EIN Presswire

Ramping Up Covid-19 Vaccination Programs: IT at Work

key vaccine program stakeholders

cvs pharmaceutical benches

Formaspace manufactures ergonomic pharmaceutical manufacturing benches at our Austin, Texas factory headquarters to help your facility operate more efficiently and help protect your workers from workplace injury and fatigue.

operation warp speed participants

height adjustable pharmaceutical workbench

Formaspace manufactured this height-adjustable pharma supply-chain workstation, which features two bin rails and built-in lighting, power supply, keyboard tray, and storage. The countertop material is phenolic resin –a common requirement for pharmaceutica

Find out how State and Federal IT systems are working together to manage data reporting for Covid-19 vaccine production and distribution.

Many Americans who rejoiced in getting the vaccination were crushed to find their appointments canceled because the federal government had missed its forecast for vaccine deliveries to the states.”

— Formaspace

AUSTIN, TEXAS, UNITED STATES, January 28, 2021 /EINPresswire.com/ — President Biden shared an encouraging note this week when he spoke to reporters about increasing the incoming administration’s daily Covid-19 vaccination goal from 1 million shots to 1.5 million shots per day.

This newfound optimism is tempered, however, by the continued rocky rollout of the vaccination program across the nation.

In the face of unprecedented demand (and limited vaccine supplies), state and local public health officials are scrambling to get vaccine shots into people’s arms as soon as possible.

The process has been frustrating all around. Many Americans who rejoiced in getting one of the highly sought after vaccination appointments were crushed to find their appointments canceled because the federal government had missed its forecast for available vaccine deliveries to the states.

Even incoming CDC director, Dr. Rochelle Walensky, admitted there is a major problem. Speaking to Fox News, she said, “I can’t tell you how much vaccine we have, and if I can’t tell it to you, then I can’t tell it to the governors, and I can’t tell it to the state health officials… If they don’t know how much vaccine they’re getting, not just this week but next week and the week after, they can’t plan. They can’t figure out how many sites to roll out, they can’t figure out how many vaccinators that they need, and they can’t figure out how many appointments to make for the public.”

Who Are The Primary Stakeholders In The Nation’s Covid-19 Vaccination Program?

To the casual observer, it may seem incomprehensible that we were able to develop, test, and authorize two Covid-19 vaccines from Moderna and Pfizer BioNTech for emergency use in less than a year but, so far, the process of managing the supply chain—from production to delivering shots into people’s arms— has been marked by frustrating delays.

Why is this the case?

Is it a redux of the 2013 healthcare.gov website rollout that crashed and burned in the days after it was launched with great fanfare by President Obama?

Unfortunately, the analogy has some merit.

As was the case with Obamacare, IT system architects working on system integration projects for the Covid-19 vaccination efforts across the country are facing a similar challenge of how to glue together a large number of decentralized database systems operated by distinct stakeholders, including the pharmaceutical industry manufacturers, at least five major federal government departments, approximately 64 state and local vaccination tracking systems, as well as approximately 255 million Americans over the age of 18.

If you are looking for your TLDR moment, this is it.

The sheer number of decentralized database systems handling protected health information (PHI) across multiple levels of government combined with the challenges posed by manufacturing the first-ever approved mRNA vaccines (which must be maintained at incredibly low temperatures and require two injections several weeks apart for each patient) is the kind of nightmare scenario that would wake up the average IT systems engineer in the middle the night screaming—with good reason!

The only good news in this complicated situation is that this program is single-payer; in other words, the federal government is footing the bill, and thus, there is no need to bring in the added complications that bedeviled the healthcare.gov rollout, such as calculating patient subsidies, insurance plan coverage, and CMS reimbursements.

Structure Of The “Operation Warp Speed” Vaccination Development Effort

Let’s take a deeper dive into each of these systems, starting with the structure of “Operation Warp Speed” (or OWS) that was launched in March 2020.

The two goals of the OWS program were to

– provide strong, direct financial backing from the federal government for any pharmaceutical company that showed a promising candidate for Covid-19 vaccines or therapeutics
– fund large-scale production of vaccine and therapeutic candidates (as well as critical items such as storage vials, syringes, PPE, etc.) in parallel to the research and development programs. In other words, the federal government foots the bill for ramping up production even before knowing whether clinical trials would pan out or not.

The federal government engaged McKesson as the chief central distribution contractor – a sensible choice since they had a track record since 2006 of managing the federal distribution of more than 1 50 million doses for influenza, chickenpox, and MMR vaccines.

OWS also brought on Palantir to provide “big data” supply chain tracking, inventory management, and data forecasting tools. In keeping with the warp speed Star Trek theme, the Palantir implementation was christened “Tiberius,” after Starship Enterprise’s Capt. Kirk’s middle name.

The company, founded by billionaire PayPal co-founder Peter Thiel, has not been without controversy, particularly among privacy advocates, who argue that the company’s data collection efforts have gone too far. Nonetheless, Palantir successfully leveraged this and other federal contracts to take the company public in late 2020.

Extraordinary Efforts To Track Deep Freeze Temperatures For Moderna And Pfizer BioNTech MRNA-Based Vaccines

Two of the Covid-19 vaccines in development worried public health officials, the ones from Moderna and Pfizer BioNTech.

These concerns multiplied when it became apparent these two vaccines would be the first to receive FDA emergency authorization.

Read more…

Julia Solodovnikova
Formaspace
+1 800-251-1505
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Psychiatric Industry Aiming to Profit from Racism, Targets African Americans

Excerpted from the Citizens Commission on Human Rights Colorado website

WASHINGTON, DC, USA, January 28, 2021 /EINPresswire.com/ — While many Americans see the recent racial tension in this country as an opportunity to address the issue of racial injustice, the psychiatric-pharmaceutical industry sees it as an opportunity to expand their reach – very profitably – into the African American community.

Psychiatrists, psychologists, and mental health groups, many funded by pharmaceutical companies, had already been arbitrarily asserting that African Americans are 20% more likely to experience serious mental health problems, and less likely to identify their own mental health problems, than the general population.

Now psychiatric practitioners are trying to create a higher level of urgency. The American Psychological Association has announced that “we are living in a racism pandemic.”

Psychiatrists and psychologists are labeling the very real pain experienced from racism as a psychiatric disorder – post-traumatic stress disorder (PTSD) – for which a standard treatment is antidepressants. These are drugs that carry the risk of serious and debilitating physical and mental side effects, including emotional blunting, worsening depression, sexual problems, birth defects, anxiety, hallucinations, agitation, violence, and suicidal thoughts and actions. Patrick D. Hahn, Affiliate Professor of Biology, Loyola University Maryland warns, “The link between antidepressants and violence, including suicide and homicide, is well established.”

American psychological and psychiatric associations have already developed guidelines on how to “treat” racism – guidelines that ensure that Black Americans are informed about psychiatric drugs as treatment.

Psychiatrists and psychologists have a long history of re-defining people’s normal responses to bad situations as “mental disorders” requiring their “treatment.” But history shows that Blacks have been especially targeted for “treatment,” and so have good reason to beware of practitioners in the psychiatric industry.

Professors Herb Kutchins and Stuart Kirk, co-authors of Making Us Crazy: DSM: The Psychiatric Bible and the Creation of Mental Disorders, state: “Defenders of slavery, proponents of racial segregation…have consistently attempted to justify oppression by inventing new mental illnesses and by reporting higher rates of abnormality among African Americans or other minorities.”

They further warn: “Innovations in diagnostic and treatment techniques are often proposed by those who claim to be committed to helping African Americans and other minority groups, but these innovations often perpetuate and increase racist thinking and lead to solutions that intensify persecution.“

For generations, psychiatrists and psychologists have been prime instigators of “scientific racism,” using pseudo-science to invent “racial diseases,” promote theories to “justify” segregation and racial population control, and subject Blacks to depraved “treatments” and barbaric psychiatric experiments.

About Citizens Commission on Human Rights: CCHR is a nonprofit, non-political, non-religious mental health watchdog. Its mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections. CCHR was co-founded in 1969 by the Church of Scientology and Professor of Psychiatry Emeritus Dr. Thomas Szasz.

The Citizens Commission on Human Rights traveling exhibit has been displayed in Washington, DC, at the Congressional Black Caucus Foundation Annual Legislative Caucus, as well as other locations. The exhibit has toured more than 441 major cities around the world and has educated over 800,000 people on the history and contemporary practices of psychiatry which are still rampant with abuse.

Excerpted from the Citizens Commission on Human Rights Colorado website: https://cchrcolorado.org/psychiatric-industry-aims-to-profit-from-racism-targets-african-americans/

Beth Akiyama
Citizens Commission on Human Rights
+1 202-349-9267
email us here
Visit us on social media:
Facebook

Psychiatric Fraud and Abuse for Profit


Source: EIN Presswire

The Pharmaceutical Drugs And Biologics Logistics Industry Encourages Reusable Packaging For Cost Efficiency

Pharmaceutical Drugs And Biologics Logistics Market Report - Opportunities And Strategies - Forecast To 2030

Pharmaceutical Drugs And Biologics Logistics Market Report – Opportunities And Strategies – Global Forecast To 2030

The Business Research Company’s Pharmaceutical Drugs And Biologics Logistics Market Report – Opportunities And Strategies – Global Forecast To 2030

LONDON, GREATER LONDON, UK, January 28, 2021 /EINPresswire.com/ — New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

Pharmaceutical logistics companies are encouraging the use of reusable packaging to transport pharmaceutical products. Reusable packaging can be made by combining aluminium-coated polyurethane, semi-active intelligent temperature-controlled containers, vacuum insulated panels and expanded polypropylene containers. Reusable containers result in lower carbon footprints than single-use packaging for pharmaceutical products, especially at high volumes. Reusable temperature-controlled packaging is also cost-efficient as compared to disposable packaging.

An example in TBRC’s pharmaceutical industry report, in 2018, Peli BioThermal, a UK based company that is engaged in providing temperature-controlled, thermally protected packaging and service solutions to the life sciences industry, launched an on demand rental program that allows the clients to receive and return the reusable Credo™ line of temperature-controlled packaging.

The global pharmaceutical drugs and biologics logistics market reached a value of nearly $90.30 billion in 2020, having increased at a compound annual growth rate (CAGR) of 4.1% since 2015. The healthcare logistics market is expected to reach $102.89 billion by 2025, and $130.03 billion by 2030.

The global pharmaceuticals and biologics logistics market is fairly fragmented, with a large number of small players. The top ten competitors in the pharmaceutical drugs market for logistics made up to 21% of the total market in 2019. Major players in the market include FedEx, UPS Inc., Kuehne + Nagel, DB Schenker, and DSV Panalpina.

Here Is A List Of Similar Reports By The Business Research Company:

Refrigerated Goods Trucking Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/refrigerated-goods-trucking-global-market-report

Global Biologics Market – By Type (Monoclonal Antibodies, Therapeutic Proteins, Vaccines), By Route Of Administration (Oral, Others (IV or IP)), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription Drugs, OTC Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2023
https://www.thebusinessresearchcompany.com/report/biologics-market

Pharmaceuticals Market – By Type (Pharmaceutical Drugs, Biologics), By Type Of Pharmaceutical Drugs (Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorder Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs), By Type Of Biologics Drugs (Monoclonal Antibodies (MAbs), Therapeutic Proteins, Vaccines), And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Global Report 2020-30: COVID-19 Impact and Recovery
https://www.thebusinessresearchcompany.com/report/pharmaceutical-contract-development-and-manufacturing-organization-cmo-market-global-report-2020-30-covid-19-impact-and-recovery

Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info


Source: EIN Presswire

Flavoring Syrup And Concentrate Industry Driven By Demand For Ready-To-Drink Beverages

Flavoring Syrup And Concentrate Market Report Opportunities And Strategies

Global Flavoring Syrup And Concentrate Market Report Opportunities And Strategies

The Business Research Company’s Flavoring Syrup And Concentrate Market Report – Opportunities And Strategies – Global Forecast To 2030

LONDON, GREATER LONDON, UK, January 28, 2021 /EINPresswire.com/ — New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

Increasing demand for ready-to-drink (RTD) beverages in the food and beverages industry is expected to drive the flavoring syrup and concentrate market in the forecast period. RTD’s are single use packaged beverages that are ready for immediate consumption at the time of purchase. Some of the popular ready to drink beverage types include cocktails, alcoholic drinks, tea, coffee. Introduction of new flavors, ease of carrying, and convenience are expected to lead to increased consumption thereby driving the demand for the flavored syrups market and the concentrates used for manufacturing them.

The global flavoring syrup and concentrate market is expected to grow from $47.82 billion in 2020 to $50.15 billion in 2021 at a compound annual growth rate (CAGR) of 4.9%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global flavored syrup and concentrate market size is expected to reach $63.92 billion in 2025 at a CAGR of 6%.

The flavoring syrup and concentrate market is segmented by type into savory spreads, syrups, sweet spreads, jam, jellies, preservatives, and molasses. The savory spreads market was the largest segment of the flavoring syrup and concentrate market segmented by type, accounting for about 39.3%. Going forward jam, jellies, preservatives segment is expected to be the fastest growing segment in the flavoring syrup and concentrate market, at a CAGR of 6.3% during 2020-2023.

Here Is A List Of Similar Reports By The Business Research Company:
Syrup, Seasoning, Oils, & General Food Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/syrup-seasoning-oils-and-general-food-global-market-report-2020-30-covid-19-impact-and-recovery

Food And Beverages Market – By Type (Alcoholic Beverages, Non Alcoholic-Beverages, Grain Products, Bakery And Confectionery, Frozen And Fruit & Veg, Dairy Food, Meat, Poultry And Seafood, Syrup, Seasoning, Oils, & General Food, Animal And Pet Food, Tobacco Products, Other Foods Products), By Distribution Channel (Supermarkets/Hypermarkets, Convenience Stores, Food Service Stores, E-Commerce and Others), By Nature (Organic, Conventional Food And Beverages) And By Region, Opportunities And Strategies – Global Food And Beverages Market Forecast To 2030
https://www.thebusinessresearchcompany.com/report/food-and-beverages-market

Functional Beverages Market – By Type (Energy Drinks, Sports Drinks, Nutraceutical Drinks, Dairy-Based Beverages, Juices, Enhanced Water, Others), By Function (Health and Wellness, Wealth Management), By Distribution Channel (Brick and Mortar, Specialty Foodservice stores, Online), And By Region, Opportunities And Strategies – Global Forecast To 2023
https://www.thebusinessresearchcompany.com/report/functional-beverages-market

Organic Soft Drinks Market Global Report 2020-30: COVID-19 Growth and Change
https://www.thebusinessresearchcompany.com/report/organic-soft-drinks-market-global-report-2020-30-covid-19-growth-and-change

Tea Capsule Market Global Report 2020-30: COVID-19 Growth and Change
https://www.thebusinessresearchcompany.com/report/tea-capsule-market-global-report-2020-30-covid-19-growth-and-change

Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Advances In Technologies Throughout The Healthcare Industry Supports The Robotic Surgery Devices Market

Robotic Surgery Devices Market Report 2020-30: Covid 19 Growth And Change

Robotic Surgery Devices Market Global Report 2020-30: Covid 19 Growth And Change

The Business Research Company’s Robotic Surgery Devices Market Global Report 2020-30: COVID-19 Growth and Change

LONDON, GREATER LONDON, UK, January 28, 2021 /EINPresswire.com/ — New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

The advances in surgical products and technologies in the healthcare industry are creating more opportunities in the surgical devices market, especially the robotic surgery systems market. Increasing investments in R&D are helping investors to create value for the customers by producing medical-surgical products like robotic surgery devices by using the latest technologies. With the use of robotic systems that are equipped with optical imaging, surgical tools, instruments, and accessories, the surgeries are made easier. Some of the surgical advances that are creating more value and opportunity in the healthcare industry include 3-D high definition endoscope (Multi-Angle Rear-Viewing Endoscopic tool) devices for brain surgery, smart surgical glasses (equipped with a video camera and head-mounted monitor) that act as computers and can be used for live observation of surgeries, surgical robots with artificial intelligence that acts as doctors, and humanoid robots which are used for highly critical surgeries in eye and brain. The other robotic surgery devices market trends include advanced surgical tools like remote robotics, which is used to assist with surgery from any remote location. Therefore, robotic surgery devices are playing an important role in the healthcare industry with their technological advancements and innovations.

The global robotic surgery devices market was expected to decline from $5.04 billion in 2019 to $4.84 billion in 2020 at a rate -3.91%. The decline was mainly due to the COVID-19 outbreak resulting in other patients delaying their episodes of care. The market is expected to stabilize and reach $7.71 billion in 2023 at CAGR of 16.81%. North America accounts for the largest share in the global market.

Here Is A List Of Similar Reports By The Business Research Company:

Robotic Surgery Services Market Global Report 2020-30: COVID-19 Growth and Change
https://www.thebusinessresearchcompany.com/report/robotic-surgery-services-market-global-report-2020-30-covid-19-growth-and-change

Minimal Invasive Surgery Devices Global Market Report 2020-30: COVID-19 Growth And Change
https://www.thebusinessresearchcompany.com/report/minimal-invasive-surgery-devices-global-market-report

Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire